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Skeletal muscleBecause myostatin normally limits skeletal muscle growth, there are extensive efforts to develop myostatin in-
hibitors for clinical use. One potential concern is that in muscle degenerative diseases, inducing hypertrophy
may increase stress on dystrophic ﬁbers. Our study shows that blocking this pathway in dysferlin deﬁcient
mice results in early improvement inhistopathology but ultimately acceleratesmuscle degeneration.Hence, ben-
eﬁts of this approach should be weighed against these potential detrimental effects. Here, we present detailed
experimental methods and analysis for the gene expression proﬁling described in our recently published study
in Human Molecular Genetics (Lee et al., 2015). Our data sets have been deposited in the Gene Expression
Omnibus (GEO) database (GSE62945) and are available at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE62945. Our data provide a resource for exploring molecular mechanisms that are related to
hypertrophy-induced, accelerated muscular degeneration in dysferlinopathy.
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Fig. 1.Microarray quality assessment of 18 chips for three biological replicates in 6 different gro
plots of 18 chips show median-centered raw data distributions. (b) Line graphs of 18 chips als
(c) The magnitude of between class variation (myostatin inhibition by ACVR2B/Fc and F66, and
biological variation to be far greater than experimental noise.
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2.1. Study design
The identiﬁcation of myostatin as a negative regulator of skeletal
musclemass raised the possibility that blocking themyostatin signaling
could have important applications for treating patients with muscle de-
generative diseases [1]. However, there is one theoretical concern that
inducing muscle hypertrophy may cause additional membrane stress,ups;wt, Dysf−/−, F66, F66;Dysf−/−, and ACVR2B/Fc-injectedwt and Dysf−/−mice. (a) Box
o support that all the chips' probes have signals of similar distribution and median value.
dysferlin deﬁciency) is compared to that of within-class variation (Error), demonstrating
Fig. 2. QQ plots wherein one-way comparisons of transcriptome change are compared between different one-way comparisons. (a) “wt versus Dysf−/−” and “wtwith ACVR2B/Fc versus
Dysf−/−with ACVR2B/Fc”: most of the transcripts that are up-regulated in ACVR2B/Fc-injectedDysf−/− (versuswtwith ACVR2B/Fc) are also up-regulated in Dysf−/− (versuswt). (b) “wt
versus Dysf−/−” and “F66 versus F66;Dysf−/−”: most of the transcripts are up-regulated only in F66;Dysf−/− (versus F66). (c) “F66 versus F66;Dysf−/−” and “wtwith ACVR2B/Fc versus
Dysf−/−with ACVR2B/Fc”: most of the transcripts are up-regulated only in F66;Dysf−/− (versus F66). As expected, the probe set representingDysf transcripts shows reduced hybridization
with RNA from Dysf−/− (versus wt), ACVR2B/Fc-injected Dysf−/− (versus wtwith ACVR2B/Fc), and F66;Dysf−/− (versus F66) muscles.
255Y.-S. Lee et al. / Genomics Data 6 (2015) 253–257causing further damage to already fragile muscle ﬁbers. To investigate
this possibility, we used both genetic and pharmacological approaches
to examine the effect of blocking myostatin in dysferlin mutant
(Dysf−/−) mice, which is a model for limb-girdle type 2B and Miyoshi
muscular dystrophies. Our rationale was that if myostatin inhibitionTable 1
Top canonical pathways from Ingenuity Pathway Analysis (IPA).
Top canonical pathways p-Value Ratio
wt versus ACVR2B/Fc-injected wt
Leptin signaling in obesity 1.14E−03 10/84 (0.119)
Cardiac β-adrenergic signaling 1.73E−03 14/158 (0.089)
G-protein coupled receptor signaling 5.04E−03 20/275 (0.073)
AMPK signaling 6.66E−03 13/169 (0.077)
Serotonin receptor signaling 6.79E−03 6/46 (0.130)
Dysf−/− versus ACVR2B/Fc-injected Dysf−/−
PI3K/AKT signaling 5.37E−03 10/144 (0.069)
14-3-3-mediated signaling 9.88E−03 9/121 (0.074)
Role of Oct4 in mammalian embryonic stem
cell pluripotency
1.1E−02 5/45 (0.111)
Assembly of RNA polymerase ii complex 1.69E−02 5/56 (0.089)
Complement system 1.84E−02 4/35 (0.114)
ACVR2B/Fc-injected wt versus ACVR2B/Fc-injected Dysf−/−
IL-10 signaling 6.78E−04 9/78 (0.115)
Hepatic ﬁbrosis/hepatic stellate cell activation 8.53E−04 13/146 (0.089)
TREM1 signaling 8.67E−04 8/71 (0.113)
Granulocyte adhesion and diapedesis 8.78E−04 15/178 (0.084)
Altered T cell and B cell signaling in rheumatoid
arthritis
2.42E−03 9/92 (0.098)
wt versus F66
Hepatic ﬁbrosis/hepatic stellate cell activation 3.68E−07 22/146 (0.151)
Inhibition of matrix metalloproteases 1.22E−06 11/40 (0.275)
Glioma invasiveness signaling 3.21E−04 10/61 (0.164)
Granulocyte adhesion and diapedesis 4.49E−04 19/178 (0.107)
Coagulation system 9.15E−04 7/38 (0.184)
Dysf−/− versus F66;Dysf−/−
Hepatic ﬁbrosis/hepatic stellate cell activation 6.25E−16 36/146 (0.247)
Fcγ receptor-mediated phagocytosis in
macrophages and monocytes
9.52E−15 29/102 (0.284)
Granulocyte adhesion and diapedesis 5.89E−12 35/178 (0.197)
Agranulocyte adhesion and diapedesis 6.81E−12 36/189 (0.190)
Leukocyte extravasation signaling 5.06E−10 35/207 (0.169)
F66 versus F66;Dysf−/−
Fcγ receptor-mediated phagocytosis in
macrophages and monocytes
2.4E−13 26/102 (0.255)
Dendritic cell maturation 1.82E−10 31/209 (0.148)
Leukocyte extravasation signaling 3.53E−10 33/207 (0.159)
Role of pattern recognition receptors in
recognition of bacteria and viruses
3.7E−10 22/106 (0.208)
Hepatic ﬁbrosis/hepatic stellate cell activation 1.09E−09 26/146 (0.178)caused increased membrane damage, these effects would be enhanced
in Dysf−/− mice, in which membrane repair is compromised [2].
For the genetic approach, we used transgenic mice expressing the
myostatin inhibitor, follistatin, exclusively in skeletalmuscle (F66 trans-
genic mice) [3], and for the pharmacological approach, we used a
soluble form of the activin type IIB receptor (ACVR2B) in which the
extracellular ligand binding domain was fused to an Fc domainTable 2
Top upstream regulators from IPA.
Top upstream regulators p-Value of
overlap
Predicted
activation
state
wt versus ACVR2B/Fc-injected wt
TNF 4.60E−08
miR-141-3p (and other miRNAs w/seed AACACUG) 3.43E−07
Lipopolysaccharide 5.11E−07
Dexamethasone 9.34E−07
GW501516 1.14E−06
Dysf−/− versus ACVR2B/Fc-injected Dysf−/−
miR-27a-3p (and other miRNAs w/seed UCACAGU) 1.78E−06
miR-128-3p (and other miRNAs w/seed CACAGUG) 1.99E−06
DYSF 6.04E−06
miR-874-3p (and other miRNAs w/seed UGCCCUG) 1.29E−05
miR-344d-3p (and other miRNAs w/seed AUAUAAC) 3.15E−04
ACVR2B/Fc-injected wt versus ACVR2B/Fc-injected Dysf−/−
DYSF 1.42E−22
Lipopolysaccharide 1.32E−20 Activated
IL1B 1.15E−17 Activated
TNF 2.06E−17 Activated
IL6 1.47E−13 Activated
wt versus F66
TGFB1 8.48E−25 Activated
IL1B 3.48E−22 Activated
TNF 2.18E−20 Activated
Lipopolysaccharide 2.88E−20 Activated
Dexamethasone 7.91E−17
Dysf−/− versus F66;Dysf−/−
Lipopolysaccharide 2.80E−58 Activated
IFNG 1.31E−41 Activated
TNF 1.32E−39 Activated
TGFB1 1.57E−39 Activated
DYSF 2.23E−32
F66 versus F66;Dysf−/−
lipopolysaccharide 1.12E−44 Activated
TGFB1 7.23E−36 Activated
IFNG 8.84E−35 Activated
DYSF 3.05E−34
TNF 5.02E−34 Activated
Table 3
Top networks from IPA.
Top networks Score
wt versus ACVR2B/Fc-injected wt
Cell-mediated immune response, cellular development,
cellular function and maintenance
65
Hematological system development and function, infectious disease,
cell-mediated immune response
54
Gene expression, cell cycle, DNA replication, recombination, and repair 49
Cell signaling, molecular transport, vitamin and mineral metabolism 47
Lipid metabolism, molecular transport, small molecule biochemistry 43
Dysf−/− versus ACVR2B/Fc-injected Dysf−/−
Hematological system development and function, gene expression,
RNA post-transcriptional modiﬁcation
87
Cellular compromise, molecular transport, nucleic acid metabolism 58
Cellular development, skeletal and muscular system development
and function, cellular movement
52
Humoral immune response, protein synthesis, cell-to-cell
signaling and interaction
52
Cardiovascular disease, cell morphology, cellular function and maintenance 51
ACVR2B/Fc-injected wt versus ACVR2B/Fc-injected Dysf−/−
Increased levels of hematocrit, increased levels of red blood cells,
inﬂammatory response
61
Cancer, cellular development, cellular growth and proliferation 60
Carbohydrate metabolism, lipid metabolism, small molecule biochemistry 53
Hematological system development and function, tissue morphology,
inﬂammatory response
47
Developmental disorder, hereditary disorder, immunological disease 46
wt versus F66
Small molecule biochemistry, cancer, gastrointestinal disease 70
RNA post-transcriptional modiﬁcation, organismal development,
renal and urological system development and function
63
Cellular movement, connective tissue disorders, cardiovascular disease 53
Lipid metabolism, small molecule biochemistry, molecular transport 52
Cell cycle, cardiovascular system development and function,
embryonic development
50
Dysf−/− versus F66;Dysf−/−
Inﬂammatory response, cardiovascular system development and function,
cardiovascular disease
58
Cancer, gastrointestinal disease, hepatic system disease 58
Connective tissue disorders, cellular assembly and organization, cellular
function and maintenance
54
Cellular development, small molecule biochemistry, cell cycle 54
Cellular movement, hematological system development and function,
immune cell trafﬁcking
51
F66 versus F66;Dysf−/−
Cellular assembly and organization, cell-to-cell signaling and interaction,
cell death and survival
84
Cellular assembly and organization, cell cycle, connective tissue
development and function
59
Cancer, reproductive system disease, neurological disease 55
Connective tissue disorders, dermatological diseases and conditions,
developmental disorder
48
Cancer, dermatological diseases and conditions, hematological disease 48
256 Y.-S. Lee et al. / Genomics Data 6 (2015) 253–257(ACVR2B/Fc) [4]. Both follistatin andACVR2B/Fc have been shown to in-
crease muscle mass in mice.2.2. Mice
To analyze the effect of F66 in Dysf−/− mice, F66 transgenic mice
were mated with Dysf−/− mice. F66;Dysf+/− males from this cross
were mated to Dysf+/− females to obtain F66;Dysf−/− and
F66;Dysf+/+ (=F66) males. Because the F66 transgene is located on
the Y chromosome, we focused all of our analysis on male mice. All
mice were maintained on a C57BL/6 background. To analyze the ef-
fect of ACVR2B/Fc administration in Dysf−/− mice, male C57BL/6
(wt) and Dysf−/− mice beginning at 6 weeks of age were given
four weekly intraperitoneal (i.p.) injections of either ACVR2B/Fc
(10 mg kg−1, i.e., 200 μg per injection) or PBS.2.3. Muscle tissues and RNA extraction
Total RNAwas extracted fromquadricepsmuscles of 10week oldwt,
Dysf−/−, F66, F66;Dysf−/−, and ACVR2B/Fc-injected wt and Dysf−/−
mice (6 different groups), and three biological replicates were set up
for each group. Quadriceps muscle (100 mg) was homogenized in
TRIzol Reagent (Thermo Fisher Scientiﬁc Inc., Waltham, MA), and RNA
was isolated from the supernatant with the RNeasy Mini Kit (Qiagen
Inc., Valencia, CA), according to the manufacturer's instructions. All
samples were treated with RNase-free DNase set (Qiagen Inc., Valencia,
CA) to remove trace amounts of genomic DNA.
2.4. Labeling and hybridization
The Ambion Expression WT kit (Thermo Fisher Scientiﬁc Inc.,
Waltham, MA) was used to label isolated total RNA, according to the
manufacturer's manual. The labeled cDNAs were hybridized onto
Affymetrix Mouse Exon 1.0 ST arrays (Affymetrix, Inc., Santa Clara, CA)
for 17 h at 45 °C with rotation (60 rpm) as described by Affymetrix in
their GeneChip Expression Analysis Technical Manual. After washing,
the arrays were scanned with Affymetrix' GeneChip Scanner 3000 7G.
2.5. Data processing
Affymetrix CEL ﬁles generated by GeneChip Command Console soft-
ware were extracted and normalized using the RobustMultichip Analy-
sis (RMA) algorithm in PartekGenomics Suite v6.6 software (Partek Inc.,
St. Louis, USA) [5]. To ensure exploration of the broadest range of gene
transcripts, we imported all 641,130 Affymetrix “Extended Meta-
probesets”. Quality control assessments were run (Fig. 1) and these
exon-level probesets were summarized into 115,830 transcripts, of
which 34,343 currently had annotation at the gene level. As the under-
standing of genomics and information on the mouse genome increase
these values will change over time, with the June 2015 annotation
showing 47,252 gene-level transcripts.
Transcription analysis used a single expression value, determined
from each transcript's exons, for transcript-level comparisons to de-
tect differential gene expression between samples under different
conditions. The one-way analysis of variance (ANOVA) was used to
determine the magnitude (fold change) and statistical signiﬁcance
(p-value) of genes' changes in expression level between sample
classes.
2.6. Data analysis
Microarray data were visualized by principal components analysis
(PCA)mapping, volcano plots, and heatmaps [6]. PCA analysis was per-
formed with the Partek platform, while volcano plots and heat maps
were generated with the Spotﬁre DecisionSite software (TIBCO
Software Inc., Boston, MA). Linear regression analyses were performed
with Spotﬁre to compare two different sets of transcriptome changes
(Fig. 2). Gene Ontology (GO; www.geneontology.org) analysis was
conducted for signiﬁcantly differentially expressed 763 genes (fold
change N2.0, p b 0.01 in wt versus F66;Dysf−/−) using Spotﬁre's Gene
Ontology Browser [7]. Canonical Pathways, Upstream Regulators, and
Network analyses were generated using Ingenuity Pathway Analysis
(IPA; QIAGEN Redwood City, CA, USA) and summarized in Tables 1, 2,
and 3. Myostatin is a transforming growth factor-ß (TGF-ß) family
member, and as expected, TGF-ß1 was a top upstream regulator in
F66mouse muscle (versus wt) (Fig. 3).
3. Conclusion
Collectively, our results demonstrated that Fst overexpression and
ACVR2B/Fc administration in dysferlin mutant mice, a mouse model
for limb-girdle type 2B and Miyoshi muscular dystrophies, induced
Fig. 3. Ingenuity upstream regulator analysis generated signaling-related networks based on published interactions with the top upstream regulator, TGFb1, in F66mouse muscle (versuswt)
based on our experimental results. Red denotes upregulation, and blue denotes downregulation of the gene. The intensity of the gene color indicates the degree of up- or down-regulation.
Orange lines indicate positive regulation, in accordance with the published interaction, blue lines indicate negative regulation, and yellow lines denote changes discordant from published
expectation. The networks were generated through the use of Ingenuity Pathway Analysis.
257Y.-S. Lee et al. / Genomics Data 6 (2015) 253–257the dramatic changes of gene expression proﬁling. Our data sets
provide a resource for exploring molecular mechanisms that are re-
lated to hypertrophy-induced, accelerated muscular degeneration
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